ascopubs.org

A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).

A prospective, multicenter trial of low-intensity focused ultrasound (LIFU) for blood-brain barrier disruption for liquid biopsy in glioblastoma (LIBERATE). This is an ASCO Meeting Abstract from the ...
ascopubs.org

A phase III, open-label, multicenter, randomized controlled trial of tunlametinib versus investigator-selected chemotherapy in patients with advanced NRAS-mutant melanoma who ...

A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I.